Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate

This article was originally published in The Tan Sheet

Executive Summary

Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains

You may also be interested in...



Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches

Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period

Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches

Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period

Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches

Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period

Related Content

Topics

UsernamePublicRestriction

Register

PS102105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel